Koeppe Tobias, Constantinescu Mihai A, Schneider Jochen, Gubisch Wolfgang
Department of Plastic and Reconstructive Surgery, Marienhospital Stuttgart, Stuttgart, Germany.
Plast Reconstr Surg. 2005 May;115(6):1723-30. doi: 10.1097/01.prs.0000161671.34502.40.
The goal of this study was to evaluate at the national level the current practice in the use of local anesthetics in cosmetic head and neck surgery and to compare the results with the novel local anesthesia technique used in the authors' department over the past 2 years.
A questionnaire was posted to all 211 board-certified members of the Association of German Plastic Surgeons. The questions related to the daily practice in rhinoplasty, blepharoplasty, otoplasty, face lift, and forehead lift. The focus was laid on anesthesia techniques, local anesthetics, vasoconstricting agents, dosages, activity onset, observed side effects, mean duration of each procedure type, and surgeon satisfaction with the anesthetic used.
A total of 86 questionnaires (40.8 percent) were returned. The overall analysis revealed that local anesthetics were used in 88.9 percent of all cosmetic procedures of the head and neck. Prilocaine 1% (Xylonest; AstraZeneca, Wedel, Germany) was the most frequently used local anesthetic (32.0 percent), followed by lidocaine 1% (Xylocaine; AstraZeneca) and mepivacaine 1% (Scandicaine; AstraZeneca). Ropivacaine 0.2% (Naropin; AstraZeneca) was used only by 1.1 percent and ropivacaine 0.75% only by 0.9 percent (including two of the authors). Approximately half of the respondents (47.2 percent) used epinephrine 1:100,000 for vasoconstriction. In face lifts, the necessity of repeated "top-up" infiltration was reported in more than half (54.7 percent) of the procedures. Ten percent of surgeons surpassed the maximum recommended dosages when working without ropivacaine. Overall adverse cardiovascular effects were reported in 5.9 percent of rhinoplasties and 8.1 percent of face lifts performed mostly with prilocaine and lidocaine. No adverse cardiovascular reactions or overdoses were noticed with the use of ropivacaine.
The survey showed a clear trend toward the increasing use of local anesthetics in cosmetic surgery of the head and neck. Although the use of prilocaine and lidocaine prevailed, adverse cardiovascular reactions in up to 8.1 percent seem high for cosmetic procedures. Furthermore, the need of additional intraoperative top-up infiltration adds to an uncontrolled cumulative effect and patient discomfort. On the basis of their positive 2 years of experience with ropivacaine, the authors strongly believe that ropivacaine offers significant advantages, both in efficacy and prolonged duration of analgesia, while reducing the risk for adverse side effects due to lesser toxicity. This observation deserves further investigation in an established comparative study.
本研究的目的是在国家层面评估头颈部整形手术中局部麻醉药的当前使用情况,并将结果与作者所在科室在过去两年中使用的新型局部麻醉技术进行比较。
向德国整形外科协会的所有211名获得委员会认证的成员发放了问卷。问题涉及鼻整形术、眼睑整形术、耳整形术、面部提升术和前额提升术的日常操作。重点在于麻醉技术、局部麻醉药、血管收缩剂、剂量、起效时间、观察到的副作用、每种手术类型的平均持续时间以及外科医生对所使用麻醉剂的满意度。
共收回86份问卷(40.8%)。总体分析显示,在所有头颈部整形手术中,88.9%使用了局部麻醉药。1%的丙胺卡因(Xylonest;阿斯利康,德国韦德尔)是最常用的局部麻醉药(32.0%),其次是1%的利多卡因(Xylocaine;阿斯利康)和1%的甲哌卡因(Scandicaine;阿斯利康)。仅1.1%的人使用0.2%的罗哌卡因(耐乐品;阿斯利康),0.75%的罗哌卡因仅0.9%的人使用(包括两位作者)。约一半的受访者(47.2%)使用1:100,000的肾上腺素进行血管收缩。在面部提升术中,超过一半(54.7%)的手术报告需要重复“追加”浸润。在不使用罗哌卡因的情况下,10%的外科医生超过了最大推荐剂量。在主要使用丙胺卡因和利多卡因进行的鼻整形术中,5.9%报告有总体不良心血管影响,面部提升术中为8.1%。使用罗哌卡因未发现不良心血管反应或过量情况。
调查显示,在头颈部整形手术中使用局部麻醉药的趋势明显增加。虽然丙胺卡因和利多卡因的使用占主导,但在整形手术中高达8.1%的不良心血管反应似乎较高。此外,术中需要额外追加浸润增加了不受控制的累积效应和患者不适。基于他们使用罗哌卡因两年的积极经验,作者坚信罗哌卡因在疗效和延长镇痛持续时间方面具有显著优势,同时由于毒性较小而降低了不良副作用的风险。这一观察结果值得在一项既定的比较研究中进一步调查。